药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02269 药明生物

已收盘 06-01 16:08:27

34.620

+1.280

+3.84%

最高35.460	最低33.600	成交量4,417万
今开33.700	昨收33.340	日振幅5.58%
总市值1,434亿	流通市值1,434亿	总股本41.41亿
成交额15.34亿	换手率1.07%	流通股本41.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":34.62,"timestamp":1780301307007,"preClose":33.34,"halted":0,"volume":44168846,"delay":0,"changeRate":0.03839232153569268,"floatShares":4140999999,"shares":4140999999,"eps":1.3446827744079246,"marketStatus":"已收盘","change":1.28,"latestTime":"06-01 16:08:27","open":33.7,"high":35.46,"low":33.6,"amount":1534339709,"amplitude":0.055789,"askPrice":34.64,"askSize":57500,"bidPrice":34.62,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":1.3446827744079246,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":33.34,"openAndCloseTimeList":[[1780277400000,1780286400000],[1780290000000,1780300800000]],"volumeRatio":1.497996,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.4583,"impliedVolPercentile":0.1911},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2640293926","title":"港股异动 | 药明生物(02269)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293926","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640293926?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:31","pubTimestamp":1780299110,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明生物(02269)涨超4%，截至发稿，涨4.26%，报34.76港元，成交额13.23亿港元。消息面上，5月31日晚，药明生物公告披露，截至今年4月30日，公司年内新签69个综合项目，其中约三分之二来自美国及欧洲市场。公司维持今年收入按年增长13%至17%的指引不变。若撇除汇率波动因素影响，收入增幅预计可达16%至20%。药明生物表示，凭借全球化CRDMO（合同研究、开发及生产）平台优势，以及持续扩大的客户基础，公司对未来增长前景保持信心。管理层预期，未来三年收入复合年增长率将达20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1242518857.USD","LU0327786744.USD","BK4588","VXUS","LU0417516738.SGD","02269","LU0181495838.USD","LU3063872942.SGD","LU0823426308.USD","LU0572944931.SGD","LU0708995583.HKD","LU0140636845.USD","LU0348735423.USD","LU0979878070.USD","LU0856984785.SGD","BK1576","LU0588546209.SGD","LU0823426480.USD","LU2039709279.SGD","LU0051755006.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0359201612.USD","SG9999002562.SGD","BK1610","LU0359202008.SGD","LU0819121731.USD","LU1242518931.SGD","LU0417516902.SGD","LU0307460666.USD","LU0516423091.SGD","BK1141","LU0456827905.SGD","LU0516422440.USD","LU0516422952.EUR","LU1720050803.USD","BK1589","BK4585","LU0348825331.USD","LU0326950275.SGD","LU0456846285.SGD","LU1794554557.SGD","LU0516422366.SGD","LU0320764599.SGD","SG9999002463.SGD","LU1880383366.USD","BK1521","LU0039217434.USD","LU1688375341.USD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153242932","title":"异动解读｜药明生物盘中上涨3.06%，4亿美元回购持续推进叠加前四月新增69个项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1153242932","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153242932?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:35","pubTimestamp":1780277709,"startTime":"0","endTime":"0","summary":"6月1日，药明生物盘中上涨3.06%，报35.04港元，成交额1.85亿港元。消息面上，公司此前宣布的不超过4亿美元股份回购计划正持续执行，5月27日至29日连续三个交易日累计回购逾450万股，合计耗资约1.50亿港元。同时，公司披露前四个月新增69个综合项目，维持全年营收同比增长13%至17%的预期，并于6月1日召开业务更新电话会议。此外，公司第18座制剂生产厂已获GMP放行投产，进一步强化从原液到制剂的一体化产能布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161715195","title":"药明生物前四月新增69个项目 维持年度营收增长预期13%-17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161715195","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161715195?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:52","pubTimestamp":1780224752,"startTime":"0","endTime":"0","summary":"据最新消息，药明生物在截至四月底的前四个月中，成功新增了69个新项目。公司同时确认，维持对全年业绩的预期，预计年度营收将实现同比增长13%至17%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423091.SGD","LU0051755006.USD","IE00B0JY6N72.USD","BK1141","LU0516422440.USD","LU0856984785.SGD","LU1242518857.USD","LU0516422366.SGD","BK1610","LU0326950275.SGD","LU0516422952.EUR","LU1880383366.USD","LU2039709279.SGD","LU0039217434.USD","LU0359201612.USD","BK1521","LU0456827905.SGD","LU0588546209.SGD","BK1589","LU0456846285.SGD","BK1576","LU3063872942.SGD","LU1794554557.SGD","LU0572944931.SGD","LU0823426480.USD","LU0819121731.USD","LU0320764599.SGD","LU0052750758.USD","LU0823426308.USD","LU0348825331.USD","LU0181495838.USD","LU1688375341.USD","LU0359202008.SGD","LU0043850808.USD","SG9999002463.SGD","02269","LU0348735423.USD","LU0307460666.USD","LU0417516902.SGD","LU1720050803.USD","LU0516423174.USD","LU0708995583.HKD","SG9999002562.SGD","LU0140636845.USD","LU1242518931.SGD","LU0327786744.USD","LU0979878070.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158853682","title":"药明生物1-4月新增69个项目，维持全年营收增长13-17%预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1158853682","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158853682?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:38","pubTimestamp":1780223895,"startTime":"0","endTime":"0","summary":"药明生物近日披露，在今年前四个月，公司成功新增了69个综合项目。这一强劲的业务增长势头，支撑了公司对全年业绩的乐观展望。\n公司重申，预计2024年全年营收将实现同比增长13%至17%。此增长预期与市场先前获取的信息保持一致，反映了公司管理层对业务持续扩张的信心。\n新增项目的持续涌入，凸显了全球生物医药研发外包需求的韧性，以及药明生物在全球产业链中的竞争优势。公司凭借其端到端的服务平台，持续吸引着来自全球生物技术公司和大型制药企业的合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764599.SGD","02269","LU0708995583.HKD","LU0359202008.SGD","BK1141","LU0516423174.USD","LU1688375341.USD","LU0140636845.USD","IE00B0JY6N72.USD","BK1610","LU0051755006.USD","LU0417516902.SGD","LU0456846285.SGD","LU3063872942.SGD","LU0043850808.USD","LU1242518857.USD","LU0181495838.USD","LU0516422952.EUR","LU0348735423.USD","LU0516422440.USD","LU1880383366.USD","SG9999002463.SGD","LU0359201612.USD","LU0516422366.SGD","LU0417516738.SGD","SG9999002562.SGD","LU0588546209.SGD","BK1576","LU0823426308.USD","LU1794554557.SGD","LU0516423091.SGD","LU2039709279.SGD","LU0327786744.USD","LU0052750758.USD","LU1242518931.SGD","LU0456827905.SGD","LU0039217434.USD","LU0819121731.USD","LU0823426480.USD","LU0856984785.SGD","LU1720050803.USD","LU0307460666.USD","LU0572944931.SGD","LU0348825331.USD","LU0326950275.SGD","BK1589","LU0979878070.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639660078","title":"药明生物：将于2026年6月1日举行业务更新电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2639660078","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639660078?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:12","pubTimestamp":1780222320,"startTime":"0","endTime":"0","summary":"南财智讯5月31日电，药明生物（02269.HK）发布内幕消息公告，公司将于2026年6月1日上午八时正及晚上八时正（香港时间）召开电话会议，就集团业务营运进行“二零二六年业务更新会议简报”。本次会议系根据《香港联合交易所有限公司证券上市规则》第13.09条及《证券及期货条例》第XIVA部有关内幕消息的规定作出，旨在向股东及潜在投资者及时披露最新业务进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755191889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0856984785.SGD","LU1794554557.SGD","LU0307460666.USD","LU0456846285.SGD","LU0052750758.USD","LU0516423174.USD","BK1610","LU1720050803.USD","LU0823426480.USD","LU0516423091.SGD","LU0979878070.USD","LU0572944931.SGD","LU0320764599.SGD","LU0819121731.USD","LU0516422952.EUR","LU0326950275.SGD","IE00B0JY6N72.USD","LU0039217434.USD","LU0051755006.USD","LU1242518931.SGD","BK1576","LU0359201612.USD","LU0327786744.USD","LU0823426308.USD","LU1880383366.USD","LU0140636845.USD","LU0417516738.SGD","LU0181495838.USD","LU0348735423.USD","BK1521","SG9999002463.SGD","LU0417516902.SGD","SG9999002562.SGD","LU0348825331.USD","LU1242518857.USD","BK1589","LU0359202008.SGD","BK1141","LU0588546209.SGD","LU3063872942.SGD","02269","LU0043850808.USD","LU0708995583.HKD","LU0456827905.SGD","LU0516422366.SGD","LU2039709279.SGD","LU1688375341.USD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151533770","title":"药明生物5月29日回购150.75万股股份，总额约4,989.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151533770","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151533770?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:56","pubTimestamp":1780059403,"startTime":"0","endTime":"0","summary":"药明生物2026年5月29日发布翌日披露报表，显示公司于5月27日、5月28日和5月29日分别回购了147.15万股、153.45万股及150.75万股普通股，分别占当日已发行股本约0.03554%、0.03706%及0.03641%。其中，5月29日回购的150.75万股系于香港联交所场内进行，每股回购价格介乎港币32.00元至33.82元，涉资约4,989.69万港元。公告显示，截至5月29日收市，公司已发行股本维持在约41.40910436亿股，暂无库藏股，已回购的股份拟注销但尚未实际注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物5月29日回购150.75万股股份，总额约4,989.69万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192701177","title":"异动解读｜药明生物盘中上涨3.15%，4亿美元回购计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=1192701177","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192701177?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:37","pubTimestamp":1780018657,"startTime":"0","endTime":"0","summary":"5月29日，药明生物盘中上涨3.15%，报33.18港元，成交额8023.59万港元。消息面上，公司于5月24日议决动用购回授权，拟在公开市场以不超过4亿美元总价格回购股份，获准购回最多4.07亿股，占已发行股份总数的10%。公司明确表示当前股价未反映其内在价值或实际业务前景。回购计划已进入实际执行阶段，公司于5月27日斥资约4991.48万港元回购147.15万股，5月28日再斥资约4989.42万港元回购153.45万股，两日合计回购逾300万股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661709","title":"药明生物于5月28日斥资4989.42万港元回购153.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661709","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639661709?lang=zh_cn&edition=full","pubTime":"2026-05-29 08:56","pubTimestamp":1780016160,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　药明生物（02269）发布公告，该公司于2026年5月28日斥资4989.42万港元回购153.45万股股份，每股回购价格为32.08-33.74港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-29/doc-inhzpnft9548611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0327786744.USD","LU0307460666.USD","LU0823426480.USD","LU0051755006.USD","LU0516422440.USD","LU0359201612.USD","LU1242518857.USD","LU0359202008.SGD","LU0823426308.USD","LU0052750758.USD","LU0456827905.SGD","LU0348825331.USD","LU0516423174.USD","LU3063872942.SGD","BK1610","SG9999002562.SGD","LU1688375341.USD","LU0417516738.SGD","LU0979878070.USD","LU0516423091.SGD","LU1242518931.SGD","BK1589","LU0140636845.USD","LU0516422952.EUR","LU0708995583.HKD","LU0320764599.SGD","LU0572944931.SGD","BK1576","BK1141","LU1880383366.USD","LU0417516902.SGD","LU0516422366.SGD","LU0588546209.SGD","LU0819121731.USD","LU0043850808.USD","LU0181495838.USD","LU1720050803.USD","LU0348735423.USD","LU2039709279.SGD","LU0856984785.SGD","LU0326950275.SGD","LU1794554557.SGD","SG9999002463.SGD","LU0039217434.USD","BK1521","LU0456846285.SGD","02269","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168651526","title":"药明生物两日合计回购3,006,000股 其中5月28日斥资约4,989.42万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168651526","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168651526?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:42","pubTimestamp":1779975746,"startTime":"0","endTime":"0","summary":"药明生物于2026年5月28日发布翌日披露公告。公告显示，公司于5月27日及28日连续两日进行股份回购与新股发行，涉及多项股本变动事宜。公告显示，上述回购股份将予以注销但截至5月28日尚未注销，公司暂无库藏股。本次发行及回购完成后，公司于5月28日的已发行股本增至4,140,910,436股。此外，公司此次回购后，在2026年6月27日之前暂不进行任何新的股份发行或出售库藏股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物两日合计回购3,006,000股 其中5月28日斥资约4,989.42万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132806411","title":"药明生物回购147.15万股股份，涉资约4,991.48万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132806411","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132806411?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:16","pubTimestamp":1779891376,"startTime":"0","endTime":"0","summary":"公告显示，公司在2026年5月8日至5月26日期间，因行使首次公开发售前购股权计划，新发行合计7.68万股普通股，发行价格区间介乎每股港币1.71元至2.64元，并占当期前已发行股本的约0.00185%。本次发行完成后，公司已发行股份总数增至约41.41亿股，库藏股份数为0股。此外，公司于2026年5月27日在香港联交所回购147.15万股，占已发行股本约0.03554%，每股回购价介乎港币33.54元至34.50元，支付总金额约4,991.48万港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物回购147.15万股股份，涉资约4,991.48万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638686651","title":"药明生物(02269)5月27日耗资约4991.48万港元回购147.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638686651","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638686651?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:07","pubTimestamp":1779890861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明生物(02269)公布，2026年5月27日耗资约4991.48万港元回购147.15万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","LU0043850808.USD","BK1589","LU1720050803.USD","LU0320764599.SGD","LU0516422952.EUR","BK1141","BK1576","LU0588546209.SGD","LU0140636845.USD","LU0856984785.SGD","LU1688375341.USD","LU0516423174.USD","LU0359201612.USD","LU0348825331.USD","LU0327786744.USD","02269","BK1610","LU1880383366.USD","LU0181495838.USD","LU0417516738.SGD","LU0823426308.USD","LU3063872942.SGD","LU0052750758.USD","LU0039217434.USD","IE00B0JY6N72.USD","LU0456827905.SGD","LU0516423091.SGD","LU0823426480.USD","LU2039709279.SGD","LU1242518857.USD","SG9999002463.SGD","LU0516422366.SGD","LU0979878070.USD","LU0572944931.SGD","LU0307460666.USD","LU0348735423.USD","LU0819121731.USD","LU0417516902.SGD","SG9999002562.SGD","LU1242518931.SGD","LU0326950275.SGD","LU0456846285.SGD","LU0708995583.HKD","LU1794554557.SGD","LU0516422440.USD","LU0359202008.SGD","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122595540","title":"药明生物第十八座制剂工厂通过GMP认证，强化一体化原料药至制剂生产能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1122595540","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122595540?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:18","pubTimestamp":1779873494,"startTime":"0","endTime":"0","summary":"药明生物宣布其第十八座制剂生产设施已成功获得GMP（药品生产质量管理规范）放行，此举标志着公司在构建从原料药到制剂的一体化端到端服务能力方面取得了重要进展。新设施的投产将进一步增强其全球供应链的稳定性和灵活性，为客户提供更高效、更完整的生物药开发与生产解决方案。这一里程碑不仅巩固了药明生物在生物制药合同研发生产组织（CDMO）领域的领先地位，也展现了其持续扩大产能以满足全球市场需求的战略决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU1242518931.SGD","LU0039217434.USD","BK1141","SG9999002562.SGD","LU1794554557.SGD","LU0856984785.SGD","LU0327786744.USD","LU0516423091.SGD","LU0823426480.USD","LU1688375341.USD","BK1521","LU0348825331.USD","LU0417516738.SGD","LU0359201612.USD","LU0823426308.USD","LU0348735423.USD","LU0979878070.USD","BK1610","LU0516422440.USD","LU0043850808.USD","LU1242518857.USD","LU0140636845.USD","LU0051755006.USD","LU0052750758.USD","LU0588546209.SGD","LU0359202008.SGD","LU0181495838.USD","LU0516422366.SGD","BK1589","SG9999002463.SGD","LU0516423174.USD","LU3063872942.SGD","LU0417516902.SGD","LU2039709279.SGD","BK1576","IE00B0JY6N72.USD","LU0516422952.EUR","LU0572944931.SGD","LU0307460666.USD","LU0456846285.SGD","02269","LU0819121731.USD","LU0456827905.SGD","LU1720050803.USD","LU0320764599.SGD","LU0326950275.SGD","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638014564","title":"药明生物直线拉升涨近7% 公司计划回购至多4亿美元的股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2638014564","media":"新浪港股","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638014564?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:39","pubTimestamp":1779763140,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　5月26日消息，药明生物直线拉升涨近7%，触及34.98港元，现成交额逾8亿港元。\n\n　　消息面上，药明生物在港交所公告，公司谨此宣布，于二零二六年五月二十四日，其已议决动用购回授权，以及 （如适用）股东于本公司股东大会上批准以购回股份的任何未来一般授权，以 不时在公开市场上以不超过4亿美元总价格购回股份。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-26/doc-inhzevaw1571104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02269","LU0823426480.USD","LU0417516902.SGD","LU0708995583.HKD","BK1576","BK1141","LU0359202008.SGD","SG9999002562.SGD","LU0052750758.USD","LU0572944931.SGD","LU0140636845.USD","LU0307460666.USD","LU0456846285.SGD","LU0516422440.USD","LU1880383366.USD","LU0856984785.SGD","LU0327786744.USD","LU0516422366.SGD","LU1688375341.USD","SG9999002463.SGD","BK1610","LU0181495838.USD","BK1589","LU3063872942.SGD","LU0326950275.SGD","LU0348735423.USD","LU0348825331.USD","LU0516422952.EUR","LU0516423174.USD","LU1794554557.SGD","LU2039709279.SGD","LU0516423091.SGD","LU0039217434.USD","LU1242518857.USD","LU1242518931.SGD","BK1521","LU0320764599.SGD","LU0051755006.USD","LU0417516738.SGD","IE00B0JY6N72.USD","LU0456827905.SGD","LU0588546209.SGD","LU0819121731.USD","LU0979878070.USD","LU0359201612.USD","LU1720050803.USD","LU0823426308.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123582529","title":"异动解读 | 药明生物盘中大涨5.01%，拟斥资不超过4亿美元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1123582529","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123582529?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:13","pubTimestamp":1779761598,"startTime":"0","endTime":"0","summary":"药明生物（02269）今日盘中大幅上涨5.01%，引起市场关注。消息面上，公司于5月24日决议动用购回授权，计划在公开市场上以不超过4亿美元的总价格回购股份。公司表示，当前的股价并未反映其内在价值或实际业务前景，此次回购计划反映了管理层对公司未来发展前景的坚定信心。此外，公司此前宣布的新加坡CRDMO中心模块化生物制剂生产厂已启动建设，建成后将成为全球规模最大的模块化生物制剂生产设施之一，这进一步增强了市场对公司长期增长潜力的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144278675","title":"异动解读｜药明生物盘中上涨4.34%，公司宣布拟斥资不超4亿美元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1144278675","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144278675?lang=zh_cn&edition=full","pubTime":"2026-05-26 09:51","pubTimestamp":1779760277,"startTime":"0","endTime":"0","summary":"5月26日，药明生物盘中上涨4.34%，报33.62港元，成交额3.89亿港元。消息面上，公司于5月26日发布公告，已于5月24日议决动用购回授权，拟不时在公开市场上以不超过4亿美元总价格购回股份，获准购回最多4.07亿股，占已发行股份总数的10%。公司明确表示，当前股份交易价格并未反映其内在价值或实际业务前景，回购计划反映公司对自身业务发展前景充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638565994","title":"药明生物(02269)：建议于公开市场上以不超过4亿美元总价格购回股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638565994","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638565994?lang=zh_cn&edition=full","pubTime":"2026-05-26 08:20","pubTimestamp":1779754855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明生物(02269)发布公告，就有关本公司股东于2025年6月6日举行的本公司股东周年大会上授出的购回本公司股份的一般授权。根据购回授权，本公司获准于香港联合交易所有限公司购回最多4.07亿股股份，占于股东周年大会当日已发行股份总数的10%。于2026年5月24日，其已议决动用购回授权，以及(如适用)股东于本公司股东大会上批准以购回股份的任何未来一般授权，以不时在公开市场上以不超过4亿美元总价格购回股份(建议股份购回)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516423091.SGD","LU1688375341.USD","LU0039217434.USD","LU0320764599.SGD","LU2039709279.SGD","LU0359202008.SGD","LU0307460666.USD","LU0588546209.SGD","LU0327786744.USD","LU0516423174.USD","SG9999002463.SGD","LU0708995583.HKD","LU0348825331.USD","LU0819121731.USD","LU1794554557.SGD","LU1242518931.SGD","LU0979878070.USD","LU0052750758.USD","LU0516422366.SGD","LU0572944931.SGD","SG9999002562.SGD","LU0516422440.USD","LU0051755006.USD","LU1720050803.USD","LU0417516738.SGD","LU0326950275.SGD","BK1141","LU0823426480.USD","LU1880383366.USD","LU0348735423.USD","LU0359201612.USD","LU0456846285.SGD","LU0456827905.SGD","LU0516422952.EUR","BK1521","BK1576","LU3063872942.SGD","LU0823426308.USD","02269","BK1610","LU0417516902.SGD","LU1242518857.USD","BK1589","IE00B0JY6N72.USD","LU0043850808.USD","LU0140636845.USD","LU0856984785.SGD","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129797493","title":"药明生物拟回购不超过已发行股本10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1129797493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129797493?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:36","pubTimestamp":1779179800,"startTime":"0","endTime":"0","summary":"药明生物于2026年5月19日发布公告，董事会建议授予一般性授权，可在股东大会通过后，于香港联合交易所有限公司等合规市场购回公司不超过提案表决当日已发行股份总数10%的股份。以2026年5月13日的实际可行日期为基准，公司已发行股份约为4,140,831,636股，回购数量上限约为414,083,163股。公司指出，除董事会认为必要的情况下，不会进行在财务或营运上可能产生重大不利影响的回购操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物拟回购不超过已发行股本10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","IE00B031HY20.USD","LU1993786604.SGD","SG9999002562.SGD","06978","AGIX","01877","LU0348767384.USD","09688","09926","02142","LU0856984785.SGD","LU0140636845.USD","01801","09995","BK1588","LU1719994722.HKD","LU0326950275.SGD","LU1226287792.SGD","ARTY","LU1960683339.HKD","LU0516422952.EUR","LU0634319403.HKD","BK1583","01177","06185","LU0572944931.SGD","LU1152091168.USD","01093","BK1161","02269","IE00BPRC5H50.USD","LU0348827113.USD","LU1303224171.USD","LU2097828631.EUR","LU0067412154.USD","06160","AIPO","159992","LU0072913022.USD","02616","LU0417516738.SGD","LU0315179316.USD","LU0456846285.SGD","LU1880383366.USD","LU1152091754.HKD","BK1589","LU0456827905.SGD","LU1226288170.HKD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636885146","title":"生物医药板块盘初普涨 药明合联(02268)涨5.24%、百济神州(06160)涨2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885146","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636885146?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:46","pubTimestamp":1779155169,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普涨，截至发稿，药明合联 涨5.24%，科伦博泰生物涨4.01%，百济神州涨2.17%，诺诚健华涨2.00%，药明生物涨1.58%，康诺亚-B涨1.35%，金斯瑞生物科技涨1.12%。消息面上，中邮证券研究表示，26年有望迎来BD和重点项目数据读出的双重催化，国产创新药全球性竞争力提升逻辑不断强化。建议关注确定性高、BD预期扰动相对小的标的。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","LU0588546209.SGD","BK1583","06160","BK4581","LU1303224171.USD","LU0516422366.SGD","BK1574","LU0708995583.HKD","BK1141","HK0000306701.USD","02269","SG9999014674.SGD","LU0417516902.SGD","01548","LU0823426308.USD","BK1161","BK1588","BK1589","LU0359201612.USD","XBI","LU0039217434.USD","LU1242518931.SGD","LU0043850808.USD","LU1719994722.HKD","LU3063872942.SGD","BK4588","09969","HK0000320264.USD","IE00B0JY6N72.USD","LU0456846285.SGD","LU0052750758.USD","161726","LU0348825331.USD","SG9999002562.SGD","LU0359202008.SGD","LU0181495838.USD","BK1576","LU0307460666.USD","LU0417516738.SGD","ONC","02268","06990","LU1251922891.USD","LU1688375341.USD","LU0320764599.SGD","LU0516422440.USD","LU1770034418.SGD","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","01801","LU2097828631.EUR","LU2399975544.HKD","IE00BZ08YR35.GBP","LU0348827113.USD","LU0326950275.SGD","BK1141","01877","BK1161","BK1574","IE00BZ08YS42.EUR","LU1969619763.USD","LU0516422952.EUR","06160","LU1242518931.SGD","159992","IE00B543WZ88.USD","LU2097828474.EUR","02269","SG9999002562.SGD","601066","LU1226287875.USD","IE00B0JY6N72.USD","LU1152091754.HKD","LU0039217434.USD","LU1152091168.USD","02616","02142","LU0588546209.SGD","IE00BZ08YT58.USD","LU0417516738.SGD","01177","LU0456827905.SGD","LU0516423174.USD","09995","LU0561508036.HKD","LU1303224171.USD","LU1688375341.USD","LU1242518857.USD","LU0359202008.SGD","06978","06185","01093","09926","IE00B5MMRT66.SGD","LU1993786604.SGD","BK1588","09688","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.0189},{"period":"1month","weight":-0.0177},{"period":"3month","weight":-0.1711},{"period":"6month","weight":0.07},{"period":"1year","weight":0.2948},{"period":"ytd","weight":0.0604}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0262},{"period":"1year","weight":0.0683},{"period":"ytd","weight":-0.0175}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}